Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?Stribild expiry date?Mebendazole ingredients?Drugpatentwatch crizotinib?How to apply for vascepa's patient assistance?
See the DrugPatentWatch profile for Tavneos
Tavneos is avacopan, a C5a receptor antagonist used for ANCA-associated vasculitis (GPA and MPA) in addition to standard therapy, to help reduce or replace long steroid use. Dosing (typical): The approved adult dose is 30 mg taken by mouth twice daily (60 mg/day) together with standard therapy. There isn’t a standard, label-approved 10 mg daily dose in the typical regimens. If you’re seeing a 10 mg tablet on a prescription or bottle: - That doesn’t match the usual labeled dosing. Your doctor or pharmacist should confirm the total daily dose and how many tablets to take each day. - Do not change the dose or tablet strength without checking with your prescriber. Common considerations: - Avacopan is metabolized by CYP3A4, so certain drug interactions can affect its levels (your clinician may adjust dosing if you’re taking strong CYP3A4 inhibitors or inducers). - It’s used with standard therapy (often including glucocorticoids and immunosuppressants). If you want, tell me: - Are you asking about what Tavneos is, or about a specific 10 mg tablet you have? - Do you have a prescription you’d like help understanding (dose, frequency, when to take)? I can also summarize side effects or look up the exact dosing details if you provide the country or your current prescription.
Other Questions About Tavneos :